Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial

Andrea Pace, Giuseppe Lombardi, Veronica Villani, Dario Benincasa, Claudia Abbruzzese, Ilaria Cestonaro, Martina Corrà, Giulia Cerretti, Mario Caccese, Antonio Silvani, Paola Gaviani, Diana Giannarelli, Marco G. Paggi
doi: https://doi.org/10.1101/2023.02.21.23286088

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Back to top
Posted July 19, 2023.
Download PDF
Data/Code
Email
Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial
Andrea Pace, Giuseppe Lombardi, Veronica Villani, Dario Benincasa, Claudia Abbruzzese, Ilaria Cestonaro, Martina Corrà, Giulia Cerretti, Mario Caccese, Antonio Silvani, Paola Gaviani, Diana Giannarelli, Marco G. Paggi
medRxiv 2023.02.21.23286088; doi: https://doi.org/10.1101/2023.02.21.23286088
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area